<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immunotherapy on FinanClub</title>
    <link>https://finan.club/tags/immunotherapy/</link>
    <description>Recent content in Immunotherapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 23 Feb 2024 09:04:30 +0000</lastBuildDate><atom:link href="https://finan.club/tags/immunotherapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Fri, 23 Feb 2024 09:04:30 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:217
Chances: ImmunityBio has completed enrollment and initial follow-up for a safety trial of its investigational cancer vaccine, showing progress in its clinical development. The company&amp;rsquo;s findings from Patient-Reported Outcomes (PROs) support positive interim results from its study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer, indicating potential efficacy of its therapies.</description>
    </item>
    
  </channel>
</rss>
